IKEUCHI
8.1.2024 13:01:28 CET | Business Wire | Press release
H. IKEUCHI & CO., LTD., a Japanese spray nozzles manufacturer, has launched a global campaign to introduce humidity control systems powered by “Dry Fog” technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240108276401/en/
Each individual photo available upon request: IKEUCHI offers humidity control systems using Dry Fog not only preventing static electricity in SMT processes but also significantly slashing operating costs and CO2 emissions.(Photo: Business Wire)
“Dry Fog” is formed out of ultrafine water droplets, each measuring 10 μm or less in diameter, generated by specialized spray nozzles. This fog rapidly evaporates into the air without wetting the objects it touches.
In the realm of surface-mount technology (SMT) processes, effective humidity control is crucial to combat electrostatic discharge (ESD) issues and challenges arising from static electricity and dry air. IKEUCHI's Dry Fog Humidification System emerges as a groundbreaking solution, delivering seven key benefits.
1. ESD Damage Prevention
As electronic components shrink, susceptibility to electrostatic discharge increases. The Dry Fog system ensures a uniform humidity level, preventing the risk of ESD damage.
2. Reduced Pick-and-Place Errors
Maintaining optimal humidity levels minimizes errors in the pick-and-place process caused by components sticking to or popping out from the tape due to static charge, boosting productivity.
3. Consistent Solder Print Quality
Humidity control during solder printing prevents issues like rapid drying or excessive moisture absorption, ensuring consistent solder print quality and product reliability.
4. Airborne Particle Reduction
Humidification curbs airborne particles, reducing defects caused by particle adherence. The Dry Fog system significantly decreases airborne particles with increased humidity.
5. Significant Operating Cost Reduction
Compared to conventional steam humidification, the Dry Fog system slashes operating costs by 68%, resulting in $50,000/year savings and a 70% CO2 emissions reduction.
6. Cooling Cost Reduction
Evaporative cooling of the Dry Fog lowers ambient temperatures, yielding an $18,000/year saving in cooling expenses at an SMT facility.
7. Healthier Work Environment
Beyond manufacturing, the Dry Fog system reduces sick leave by maintaining a relative humidity of 50% or above, leading to fewer sick days during winter.
In conclusion, IKEUCHI's Dry Fog Humidification System is a comprehensive solution addressing crucial aspects of SMT processes, enhancing productivity, reducing costs, and fostering a healthier workplace. This technology offers a transformative approach to humidity control in electronics manufacturing.
Links to Articles: Part 1, Part 2, Part. 3
Network: U.S., Europe, China, Taiwan, Indonesia, Thailand, Japan
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240108276401/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
